Introduction
Opiate agonist therapies for opiate dependence lower HIV incidence and arrest rates among injection drug users, [1] [2] [3] thus enhancing access to these treatments is a major public health priority. Buprenorphine, a partial opiate receptor agonist approved by the US FDA in 2002 for treatment of opiate dependence, offers important advantages over methadone maintenance. Buprenorphine is less lethal in overdose than methadone. 4 The most commonly prescribed formulation of buprenorphine, in which it is combined with the opiate antagonist naloxone, produces opiate withdrawal when injected, limiting its abuse potential. 5 Because of these lower risks, buprenorphine can be prescribed by office-based generalist physicians, potentially increasing treatment access and reducing stigma in comparison to methadone, 6 which is restricted to federally regulated methadone clinics.
Few physicians offer buprenorphine treatment despite its advantages. 7 While policies such as state Medicaid coverage of buprenorphine are related to physician adoption 8, 9 and while Federal and regional initiatives have sought to increase the number of prescribers, the number remains inadequate to care for opiate-dependent people, 10 particularly among low-income patients. For example, based on a comparison of the Federal register of buprenorphine-certified prescribers published by the US Substance Abuse and Mental Health Services Administration, with the New York City Medicaid provider network provided by the New York State Medicaid office as of 2012, only 94 of the 899 buprenorphine-certified prescribers in the five boroughs of New York City (10.4%) accept Medicaid payments. In contrast, Medicaid pays for a large percentage of methadone patients in New York City. 11 The way that opiate-dependent people find their way to treatment also differs by medication: Buprenorphine providers are listed on an internet site and rely on patients' initiative and access to web-based resources, while methadone clinics get referrals from a wide range of agencies serving low-income people, including public health clinics, social welfare offices, and the criminal justice system. [12] [13] [14] As might be predicted based on these differences in provider characteristics and treatment referral pathways, national data regarding the demographic characteristics of patients treated with buprenorphine indicate racial/ethnic and socioeconomic disparities in its use. National surveys of buprenorphine and methadone patients revealed that buprenorphine patients were more likely to be White (92 vs. 53% of methadone patients), employed (56 vs. 29%), to have some college education (56 vs. 19%), and that 75% were prescription opioid dependent rather than heroin dependent. 15 Since buprenorphine has been disproportionately taken up by prescription opioid-dependent patients in rural and suburban areas, these national data may not represent usage in major US cities. Little is known about racial, ethnic, and socioeconomic patterns of buprenorphine treatment in major metropolitan areas, where impoverished ethnic minorities are residentially concentrated and where the prevalence of heroin injection-and associated risks of infection and overdose-is high. The geographic concentration of poverty in American cities and its relationship to enduring racial/ ethnic segregation are well-documented phenomena, 16, 17 leading to increased risk of interrelated health problems such as substance abuse, HIV, hepatitis C, and diabetes. 18 The disparate geographic dissemination of corresponding treatments therefore has important implications for public health. This is particularly relevant to New York City, the largest city in the USA, with residentially concentrated poverty, the greatest number of opioid abusers (of heroin or illicit opioids) with estimates ranging from 92,000 to 200,000, and only 21,600 of these initiating treatment in 2006. 19, 20 New York City also has the highest AIDS case rate of any US city. 21, 22 Additionally, the New York City Department of Health took initiative as early as 2003 to promote buprenorphine in its public hospitals as an HIV prevention measure, and New York State Medicaid covers buprenorphine prescriptions. Based on the size of its opiate-dependent population, the impact of HIV on this population, and the early efforts of local officials to make buprenorphine accessible to low-income patients, New York City offers an important study of buprenorphine uptake in urban, low-income, and ethnic minority areas.
Existing New York City data were used to examine the correlation of residential area-level measures of poverty, race, and ethnicity with rates of buprenorphine and methadone treatment use. The hypothesis tested is that methadone treatment rates are the highest in the residential areas with the lowest incomes and highest percentages of black and Hispanic residents, while buprenorphine treatment rates are the highest in the residential areas with the highest incomes and lowest percentages of black and Hispanic residents.
Method
Data The study conducts secondary analyses of data collected for administrative purposes. Buprenorphine use is determined from data collected by the Federal Drug Enforcement Agency (DEA) on the number of outpatient buprenorphine prescriptions written in 2007 by postal zip code of the patient treated, supplied to the authors by the New York State Bureau of Narcotics Enforcement. Although independent verification of the completeness of these data is not available, it is the most complete publicly available data set on buprenorphine prescriptions because retail pharmacies are federally mandated to report the age, address, and date of service for each buprenorphine prescription recipient to the DEA. Data on methadone use were obtained from the New York State Office of Alcoholism and Substance Abuse Services and are the number of all patients in a postal zip code receiving methadone maintenance in methadone clinics in New York City in 2007. Estimates of missing data in this set are unavailable, but missing data are expected to be rare since all New York City methadone maintenance clinics are regulated by the New York State Office of Alcohol and Substance Abuse Services, and this data set is linked to reimbursements and used for budgeting purposes. To describe zip codes, data on the proportions of the population who are living at less than two times below the poverty level, are Black nonHispanic, and Hispanic were obtained from 2000 US Census ZIP Code Tabulation area reports. Postal zip codes were matched into census zip code equivalents 23 to align them with census data. After exclusion of codes denoting water areas and non-residential areas, the sample consisted of 181 New York City census zip codes.
Measures Annual buprenorphine and methadone treatment rates were calculated for persons living in each zip code who had received treatment within the year. To be noted is that persons living in these zip codes, as is likely in NYC, could have traveled to other zip codes for their treatments. The annual total number of buprenorphine prescriptions (n027,571) written to patients residing in each zip code was divided by 12 to approximate an unduplicated number of persons receiving prescriptions. To obtain a rate, this number was divided by the number of persons residing in the zip code. The particular divisor used to unduplicate the count does not impact the analysis conducted. The methadone treatment rate was defined as the annual total number of people in a zip code enrolled for any period of time in a methadone clinic (n039,231), divided by the number of persons residing in the zip code. The buprenorphine and methadone treatment rates are in different units and hence not directly comparable. The study focus, however, is to separately assess the dissemination pattern of each medication, buprenorphine and methadone, among NYC residential areas. To accomplish this, separate comparisons of each usage rate were made among aggregations of zip codes that were homogeneous with regard to income and race/ethnicity (social areas defined below).
Social areas Social areas are residential areas in which persons have similar living standards, ethnic backgrounds, and lifestyle. [24] [25] [26] [27] For this study, zip codes were aggregated into social areas based on similarities in zip code racial/ethnic and income characteristics. Social area analysis is an established approach used in public health research to examine effects of residential characteristics on health and behavior and to examine inequalities in health, when residential information is available for each subject but not other demographic information. [28] [29] [30] [31] Social areas were formed based on the three census variables that capture income and race/ ethnicity using Ward's minimum-variance method in the SAS 9.2 cluster procedure. 32 Starting with a pre-specified number of social areas, the procedure clusters zip codes to minimize within-cluster variance over the three variables. A heuristic procedure was used to select the optimal number of clusters for ANOVA analyses of treatment rates. The results of clustering based on increasing numbers of social areas were reviewed. The final choice of the number of social areas was based on (1) having enough clusters to minimize within-cluster variance and (2) having few enough clusters to have a sufficient number of zip codes (the unit of analysis) to maximize power in the analysis of variance. Five social areas were selected. Given that only publicly available aggregate (zip code level) data without personal identifiers were used in this study, the study was exempted from informed consent procedures by the Human Subject Review Boards of New York University and of Nathan Kline Institute for Psychiatric Research.
Statistical analyses Two levels of ecological analyses were conducted between treatment rates and neighborhood characteristics. First, zip code level treatment rates were related to income and racial/ ethnic proportions of a zip code. Each rate was correlated univariately with race/ethnicity and income using Pearson's product-moment correlation coefficient. Significance is reported at the 1% level. While ANOVAs (or regression models) on zip codes might have been used for this analysis, multiple interaction terms would have been required in the models, and their effects are notably difficult to interpret. Second, ANOVA models were use to compare treatment rates among social areas defined by the three census variables. A one-way analysis of variance was used to compare mean treatment rates of each (the average of rates across the zip codes in a social area) among the five social areas. Rates between areas were contrasted using the Tukey studentized range test for pairwise comparisons corrected for multiplicity, which controls the family wise error rate at the 5% level. No variables were controlled for in the analysis of variance since the social area itself encapsulates race, ethnicity, and income. No zip code level data were available on insurance status, which could have impacted use; however, in the USA, income level and ethnicity are correlated with percent persons with insurance coverage. 33, 34 All study analyses were conducted in SAS 9.2.
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Results
Zip code level analyses Across zip codes, the buprenorphine treatment rate was significantly (pG0.01) negatively correlated with percent of residents who are in poverty, Black non-Hispanic, and Hispanic while methadone rates were significantly (pG0.01) positively correlated with these variables (see Table 1 ). Methadone rates were substantially (R90.55) correlated with percent poverty and percent Hispanic. Buprenorphine rates were weakly correlated with all census variables (RG−0.29).
Social area analyses In order to better describe the social areas in terms of the census variables (percent of a characteristic), each characteristic was assigned a value of high (H), medium (M), or low (L) based on cut points obtained from a one-dimensional clustering of the variable values across all zip codes into three tertiles. The tertile cut points for percent below two times poverty Table 2 ). The clusters were mainly but not necessarily geographically contiguous (see Fig. 1 ). The social area L,L,L had the highest rate of buprenorphine users, and this rate significantly differed from rates of all other social areas (pG0.05 for all contrasts (see Table 3 ). Methadone treatment rates were the highest in social area 5 (H,M,H). Methadone treatment rates monotonically increased from social areas 1 to 5 from a low of 21 persons per 10,000 in the highest income area to a high of 114 persons per 10,000 in the poorest area. The methadone rate for the high poverty area that was predominately Hispanic differed significantly from the rates of all other social areas. The high poverty area with moderately high proportions of both Blacks and Hispanics (H,M,M) had significantly higher rates of methadone use than the low poverty, predominately White area (L,L,L), and the moderate income area with moderate proportions of Blacks and Hispanics (M,M,M).
Discussion
Since demographic data on individual buprenorphine users are not routinely collected, information relevant to the population level distribution of buprenorphine treatment, relative to methadone treatment, has not been available at the regional level. This paper is unique in its comparison of buprenorphine with methadone usage patterns by the demographics of the neighborhoods of users, providing insight into dissemination patterns. It was found that buprenorphine treatment is unevenly distributed among New York City social areas and is concentrated in areas with the highest incomes and highest percentage of White residents. Zip code level findings of a negative correlation of buprenorphine treatment rates, and a positive correlation of methadone treatment rates with poverty and Black or Hispanic ethnicity was confirmed by social area level multivariate analysis which shows that methadone has an inverse geographic distribution to that of buprenorphine. 36 it launched an outreach campaign to public clinics which distributed promotional materials on buprenorphine and offered buprenorphine certification training for public clinic physicians. Although the impact of these efforts on buprenorphine dissemination in public clinics has not been systematically evaluated because few other major US cities promote buprenorphine for publicly insured patients, and not all states' Medicaid programs cover buprenorphine prescriptions, 8 differences in New York City by social area may be smaller than those in other cities.
The low number of Medicaid-accepting buprenorphine prescribers relative to the potential demand for buprenorphine suggests a problem of access to buprenorphine prescribers among lowincome people. In contrast, buprenorphine usage in high-income, largely White areas is most likely linked to providers who accept private insurance coverage. Furthermore, the dissemination of buprenorphine as a viable treatment may be promoted by social networks of neighborhood residents who share treatment information; such networks have been shown to reinforce socioeconomic and ethnic/racial differences in treatment. 37 Availability of providers in a zip code could potentially impact the dissemination of the two medications. However, the widespread availability of mass transit in New York City would strongly mitigate the effect of provider location on treatment provision. A shortage of public sector physicians who prescribe buprenorphine has been identified as a major barrier to dissemination among low-income patients in a national study, and most buprenorphine prescribers are in private practice or are addiction specialists. 9 Interviews with buprenorphine prescribers reveal that private practice physicians charge substantial fees for buprenorphine treatment, while there are few professional or economic incentives for public sector physicians to offer buprenorphine treatment (Hansen H, unpublished data). Table 3 Mean annual number of buprenorphine and methadone treatments per 10,000 residents (treatment rates), by social area Social area treatment rates contrasted using the Tukey studentized range test for pairwise comparisons corrected for multiplicity, controlling family wise error rate at the pG0.05 level L low tertiles of variables within social area, M medium tertiles of variables within social area, H high tertiles of variables within social area, SE standard error a Significantly greater than the buprenorphine treatment rates for social areas 2, 3, 4, and 5 b Significantly less than the buprenorphine treatment rate for social area 1 c Significantly less than the methadone treatment rates for social areas 4 and 5 d Significantly less than the methadone treatment rates for social area 5 e Significantly greater than the methadone treatment rate for area 1 f Significantly greater than the methadone treatment rates for social areas 1, 2, 3, and 4
Other factors that may contribute to the low rates of buprenorphine treatment in low-income and ethnic minority neighborhoods could be linked to professional and institutional treatment biases. These factors include: (1) Some addiction specialists express the view that buprenorphine is more clinically appropriate for employed, "stable" prescription opiate abusers than "unstable" heroin injectors; 38, 39 ( 2) The manufacturer's marketing of buprenorphine relies on Internet-based publicity displaying employed, White prescription opiate abusing patients, 40 which may reflect that buprenorphine was approved for treatment of opiate dependence on the heels of a major US epidemic of White, middle class prescription opiate abuse; 41 (3) A major mechanism for referral of patients to buprenorphine-certified physicians is an online network sponsored by the federal Substance Abuse and Mental Health Services Administration; 42 low-income patients may not have access to online services.
Research and interventions to identify and redress the institutional and professional barriers to buprenorphine provision are needed. Effective dissemination of buprenorphine requires targeted efforts to promote buprenorphine prescribing among public sector physicians, particularly those in primary care who come into contact with large numbers of patients. Studies of buprenorphine dissemination through the NIDA Clinical Trials Network, and of the Physician Clinical Support System, indicate that linking buprenorphine experienced providers with inexperienced providers is effective in promoting buprenorphine prescription by widening circles of physicians. 43 Physicians are also more likely to prescribe buprenorphine when they believe their patient population has a need for treatment for opioid dependence and when they perceive the treatment as relatively easy to administer. 44 These perceptions could be addressed in interventions that promote buprenorphine accessibility in public clinics.
Unlike buprenorphine treatment, methadone maintenance is targeted to low-income patients. Methadone clinics have long been funded by city and state governments, and methadone is considered one of New York City's major HIV prevention initiatives and is routinely offered to opiate-dependent recipients of public assistance. 13 There is, however, little clinical evidence of any advantage of methadone over buprenorphine for treatment of low-income patients. A clinical trial comparing buprenorphine with methadone treatment of low-income opiate-dependent arrestees initiating treatment prior to prison release found no difference between patients in the two groups with regard to relapse, re-arrest, or re-incarceration after release; in fact, treatment continuation rates were higher among those on buprenorphine. 45 Other studies suggest that patient preferences for, and outcomes on, buprenorphine are influenced by disease severity and co-morbidity; 46, 47 these factors should also be examined in future investigations of geographic and demographic patterns in buprenorphine dissemination.
This study has several limitations. The ethnic and socioeconomic backgrounds of buprenorphine and methadone users cannot be directly inferred from the characteristics of the area of their residence due to the risk of ecological fallacy. The ecological fallacy occurs when population level characteristics are ascribed to individuals in the area who do not have these characteristics, e.g., by assuming that all persons in a predominantly Black area are Black. Refraining from making inferences about how individual characteristics influence treatment avoids the ecological fallacy, but does not allow for extrapolating from geographic distribution of treatment use to the characteristics of individual treatment users. Second, unmeasured neighborhood characteristics which influence methadone and buprenorphine treatment rates-such as disease prevalence, incidence, and severity-may be heterogeneously distributed across neighborhoods and may confound the relationships observed. Third, the estimate of the unduplicated count of buprenorphine users does not reflect the possible mixed frequency of prescription fillings. In any event, direct comparisons are not made between buprenorphine and methadone treatment rates within a social area or zip code due to differences in their units of measurement. Fourth, the US Census demographic data used were collected 7 years before the buprenorphine treatment data. Shifts in neighborhood population characteristics may have occurred in that time. Finally, New York City findings may not be generalizable to other US cities.
Implications for Behavioral Health
The unequal distribution of the new, lower-risk treatment technology reported here is predicted by social epidemiological theory: new technologies disproportionately benefit high-income consumers with the means to access them. Therefore, treatment innovations can widen disparities unless concerted public efforts counteract social processes underlying disparities. 48, 49 In addition, analyses that take into consideration the interaction of geographic patterns of health and health care with local cultural and institutional practices are crucial for developing appropriate and context-dependent interventions. 50 For example, access to a full range of convenient, safe treatments for opiate dependence in low-income, and ethnic minority neighborhoods is a particular public health imperative because the most severe consequences of untreated opiate dependence-HIV infection, overdose, and incarceration-are concentrated there. Physicians serving low-income patients already face the challenge of growing caseloads and declining reimbursements due to reduced governmental support for the public health sector. In New York State, providers saw $204.9 million in cuts Medicaid for mental health services between 2009 and 2012 51 and $46 million in cuts to the Office of Alcoholism and Substance Abuse in 2011 alone. 52 Specific physician incentives to increase the number of buprenorphine prescribers in the public sector-those who serve the largest number of patients at risk for opiate related infection, overdose, and incarceration-should be considered as a preventive health investment. Follow-up studies of the physician-level, institutional, and policy factors related to the adoption of buprenorphine should provide information to refine treatment dissemination interventions and achieve the public health gains heralded with the introduction of buprenorphine treatment.
